Clinical Trials Logo

Helicobacter Pylori Infection clinical trials

View clinical trials related to Helicobacter Pylori Infection.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06396780 Active, not recruiting - Clinical trials for Helicobacter Pylori Infection

Treatment Adherence And Influencing Factors in Children With Helicobacter Pylori Infection During Eradication Therapy

Start date: March 30, 2024
Phase:
Study type: Observational

The aim of this study is to describe the current status of treatment adherence in children with Helicobacter pylori infection, understand the medication literacy, medication beliefs of the children, knowledge of H. pylori among caregivers, medication beliefs, medication support, and explore the influencing factors of medication adherence.

NCT ID: NCT05749081 Active, not recruiting - Clinical trials for Helicobacter Pylori Infection

Helicobacter Pylori and Lacidophilin Tablets in Combination With Vonorazan Dual Therapy

Start date: May 13, 2023
Phase: Phase 4
Study type: Interventional

Our previous study included 119 Helicobacter pylori(H. pylori)-infected Chinese patients without previous eradication history who were randomized to low-or high-dose amoxicillin-vonoprazan regimens consisting of amoxicillin 1 gram either b.i.d. or t.i.d plus vonoprazan 20 mg b.i.d for 7 or 10 days. Neither 7-or 10-day VA dual therapy with either b.i.d. or t.i.d. amoxicillin achieved satisfied efficacy (i.e., <90%) when given as first-line treatment for H. pylori infection. Lacidophilin tablets have been reported to increase the eradication rate of H. pylori while reducing the incidence of adverse effects.This study evaluated the efficacy and safety of lacidophilin tablets in combination with amoxicillin-vonoprazan dual therapy for 10 days as first-line treatment for H. pylori in China.

NCT ID: NCT05647278 Active, not recruiting - Clinical trials for Helicobacter Pylori Infection

A RCT of the Efficacy of Tegoprazan 50mg QD in the Treatment of Helicobacter Pylori Infection ( TATH-1 )

TATH-1
Start date: November 1, 2022
Phase: Phase 4
Study type: Interventional

The treatment of helicobacter pylori is very important. The routine treatment is quadruple therapy. In recent years, double therapy has appeared and the curative effect is fair. However, antacid generally uses proton pump inhibitor. The proton pump inhibitor needs double dose to achieve good antacid curative effect. The effect of Tegoprazan used for inhibiting gastric acid is better than proton pump inhibitor. At present, some studies use Tegoprazan instead of common proton pump inhibitor, but almost all use double dose of Tegoprazan. In the previous study, we found that the effect of double dose of proton pump inhibitor can be achieved with 50mg QD of Tegoprazan. Therefore, in this study, 50mg QD of Tegoprazan was used to replace the double dose of proton pump inhibitor to observe the antibacterial effect of Tegoprazan on Helicobacter pylori.

NCT ID: NCT05631015 Active, not recruiting - Gastric Cancer Clinical Trials

Artificial Intelligence for Determination of Gastroscopy Surveillance Intervals

Start date: January 1, 2012
Phase:
Study type: Observational

The purpose of this study is to develop and validate a clinical decision support system based on automated algorithms. This system can use natural language processing to extract data from patients' endoscopic reports and pathological reports, identify patients' disease types and grades, and generate guidelines based follow-up or treatment recommendations

NCT ID: NCT04674774 Active, not recruiting - Clinical trials for Helicobacter Pylori Infection

Efficacy of Tegoprazan Based Bismuth Quadruple Therapy for Helicobacter Pylori Infection

Start date: March 4, 2021
Phase: N/A
Study type: Interventional

This study aims to investigate eradication rate, drug compliance, and adverse events in patients with confirmed Helicobacter pylori infection between tegoprazan, bismuth, metronidazole, and tetracycline for 14 days (TBMT) and PPI, bismuth, metronidazole, and tetracycline for 14 days (LBMT)

NCT ID: NCT03541876 Active, not recruiting - Clinical trials for Helicobacter Pylori Infection

French Pediatric Helicobacter Pylori Observatory

GFHPP
Start date: January 9, 2018
Phase:
Study type: Observational [Patient Registry]

Helicobacter pylori is a major human pathogen associated with significant morbidity. The treatment oriented by the antibiogram or PCR (Polymerase Chain Reaction) should be privileged in children. However, the optimal treatment for the eradication of pediatric H. pylori infection is still not established. No French consensus conference on the management of H. pylori infection in children taking into account the epidemiological data available for this infection has been published. The description of diagnostic and therapeutic management procedures has not yet been specifically described according to the country of birth of children. The main objective is to collect data enabling the establishment of a French observatory of Helicobacter pylori in children in order to provide a national database.

NCT ID: NCT03397680 Active, not recruiting - Clinical trials for Helicobacter Pylori Infection

Effectiveness of Once-daily Dose Regimen of 7-day and 14-day High Dose Rabeprazole-levofloxacin Based Quadruple Therapy for H. Pylori Eradication in Thai Patients With Non-ulcer Dyspepsia

Start date: May 15, 2017
Phase: Phase 1
Study type: Interventional

H.pylori is an organism which causes gastric inflammation, peptic ulcer disease (PUD), mucosa associated lymphoid tissue (MALT) lymphoma and gastric cancer. Practical guideline for treatment of patients with dyspepsia and H.pylori eradication recommended the 14-day triple therapy regimen which had curable about 70% by using proton pump inhibitor (PPI) combined with antibiotics including amoxicillin, clarithromycin and metronidazole. Up to date, there has been no evidence about the cure rate for H.pylori eradication with once-daily dose regimen of high dose rabeprazole and levofloxacin based therapy. This research is to study the 7-day and 14-day cure rate of H.pylori eradication treatment with once-daily regimen of high dose rabeprazole-levofloxacin based quadruple therapy.

NCT ID: NCT03220542 Active, not recruiting - Clinical trials for Helicobacter Pylori Infection

The Effect of Broccoli Sprout Extract and Probiotics for Eradication of Helicobacter Pylori

Start date: January 2016
Phase: Phase 4
Study type: Interventional

In Korea, the first-line therapy to treat Helicobacter pylori (Hp) consists of a proton pump inhibitor (PPI) and two antibiotics for one week. But, eradication has become less successful due to low compliance and high resistance to the antibiotics. Therefore, it is necessary to develop new treatment strategies that increase the eradication rate and reduce adverse effects. In vitro study, we previously reported that a broccoli sprout extract containing sulforaphane may prevent lipid peroxidation in the gastric mucosa and play a cytoprotective role in Hp-induced gastritis. Also, several studies suggested that probiotics could be effective for improving Hp eradication rate or reducing adverse events. But, their effect for eradication of Hp is not yet conclusive. The aims of this prospective study is to investigate the efficacy of a broccoli sprout extract containing sulforaphane and probiotics for eradication of Hp, compared with standard triple therapy.

NCT ID: NCT03130452 Active, not recruiting - Clinical trials for Helicobacter Pylori Infection

Helicobacter Pylori Eradication Study

Start date: February 1, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study was to evaluate the efficacy and compliance of tailored therapy which using the polymerase chain reaction for point mutation of clarithromycin, compared to concomitant therapy, in patients without history of H. pylori eradication.

NCT ID: NCT02407119 Active, not recruiting - Clinical trials for Helicobacter Pylori Infection

Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD

Start date: June 2003
Phase: Phase 3
Study type: Interventional

This study evaluates whether Helicobacter pylori eradication improves precancerous lesions including glandular atrophy and intestinal metaplasia as well as metachronous cancers or dysplasias after endoscopic mucosal resection for gastric cancer.